Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Microinvasive breast carcinoma

Laura C Collins, MD
Christine Laronga, MD, FACS
Julia S Wong, MD
Section Editors
Lori J Pierce, MD
Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)
Daniel F Hayes, MD
Deputy Editor
Sadhna R Vora, MD


Microinvasive breast carcinoma is defined as invasive carcinoma of the breast with no invasive focus measuring more than 1 mm [1]. It is almost always encountered in the setting of ductal carcinoma in situ (DCIS); thus, it is commonly referred to as ductal carcinoma in situ with microinvasion. It is less commonly seen in association with lobular carcinoma in situ (LCIS) or in the absence of carcinoma in situ.

The epidemiology, clinical presentation, pathology, and treatment of microinvasive breast carcinoma will be reviewed here. DCIS and LCIS are presented separately.

(See "Ductal carcinoma in situ: Treatment and prognosis".)

(See "Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis".)

(See "Atypia and lobular carcinoma in situ: High-risk lesions of the breast".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jan 16, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.
  2. Sue GR, Lannin DR, Killelea B, Chagpar AB. Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. Am J Surg 2013; 206:478.
  3. Vieira CC, Mercado CL, Cangiarella JF, et al. Microinvasive ductal carcinoma in situ: clinical presentation, imaging features, pathologic findings, and outcome. Eur J Radiol 2010; 73:102.
  4. Padmore RF, Fowble B, Hoffman J, et al. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience. Cancer 2000; 88:1403.
  5. Silverstein MJ, Lagios MD. Ductal carcinoma in situ with microinvasion. In: Ductal Carcinoma in Situ of the Breast, Silverstein MJ (Ed), Lippincott Williams and Wilkins, Philadelphia 2002. p.523.
  6. de Mascarel I, MacGrogan G, Mathoulin-Pélissier S, et al. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 2002; 94:2134.
  7. Adamovich TL, Simmons RM. Ductal carcinoma in situ with microinvasion. Am J Surg 2003; 186:112.
  8. Margalit DN, Sreedhara M, Chen YH, et al. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol 2013; 20:811.
  9. Hahn SY, Han BK, Ko EY, et al. MR features to suggest microinvasive ductal carcinoma of the breast: can it be differentiated from pure DCIS? Acta Radiol 2013; 54:742.
  10. Parikh RR, Haffty BG, Lannin D, Moran MS. Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys 2012; 82:7.
  11. Solin LJ, Fowble BL, Yeh IT, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 1992; 23:961.
  12. Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer 1998; 82:2382.
  13. Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990; 125:1298.
  14. Prasad ML, Osborne MP, Giri DD, Hoda SA. Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol 2000; 24:422.
  15. Wong SL, Chao C, Edwards MJ, et al. Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes. Am J Surg 2002; 184:492.
  16. Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000; 7:636.
  17. Zavagno G, Belardinelli V, Marconato R, et al. Sentinel lymph node metastasis from mammary ductal carcinoma in situ with microinvasion. Breast 2007; 16:146.
  18. Pimiento JM, Lee MC, Esposito NN, et al. Role of axillary staging in women diagnosed with ductal carcinoma in situ with microinvasion. J Oncol Pract 2011; 7:309.
  19. Kapoor NS, Shamonki J, Sim MS, et al. Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer. Ann Surg Oncol 2013; 20:2576.
  20. Lyons JM 3rd, Stempel M, Van Zee KJ, Cody HS 3rd. Axillary node staging for microinvasive breast cancer: is it justified? Ann Surg Oncol 2012; 19:3416.